Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Silverback Therapeutics, Inc. (the “Company”) (NasdaqGM: SBTX) with ARS Pharmaceuticals, Inc. pursuant to which Silverback shareholders will end up owning just approximately 37% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at , or visit https://www.ksfcounsel.com/cases/nasdaqgm-sbtx/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221014005545/en/